Alvotech (ALVO) Stock

About Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

Alvotech is led by CEO Lisa Graver, employs 1,012 people, headquartered in IS, publicly traded since 2022.

Alvotech (ALVO) stock trades at $4.58 with a market capitalization of $1.63B. The stock is valued at a negative price-to-earnings (P/E) ratio of -8.85, reflecting a net loss over the last twelve months, a negative price-to-book of -9.63, reflecting negative shareholders' equity, price-to-sales of 3.75. Over the past 52 weeks the stock has ranged between $2.94 and $8.50, and currently trades 46.1% below its 52-week high.

On profitability, Alvotech generates a return on equity (ROE) of 76.83% (not meaningful, as shareholders' equity is negative), return on capital employed of 3.77%, an operating margin of 13.31%, a net profit margin of -36.51%.

Official website: www.alvotech.com

Alvotech by the numbers, 2019–2025

Between 2019 and 2025 Alvotech reported revenue of $32.0M rising to $586.0M, a change of +1731.3% across 7 years. Compounded, revenue has grown 54.3% a year over five years, 91.8% over three, 19.6% over the last twelve months. Net profit rose to $28.0M.

Operating margin went from -192.5% in 2019 to 13.3% in 2025, a gain of 205.9 percentage points. The most recent net margin is -36.51%. On a trailing twelve-month basis to Jun '26, revenue is $492.0M and net profit $-180.0M.

Borrowings stand at $1.4B, cash from operations was $-50.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged 54.3% over five years, and was -9.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Alvotech (ALVO) — frequently asked questions